Barbara Rauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barbara Rauer has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Dennis Kim
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
1 shared publication - Hal M. Hoffman
Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, USA
1 shared publication - Hugh H. Tilson
Gillings School of Global Public Health, University of North Carolina at Chapel Hill
1 shared publication - Jasmin Beate Kuemmerle-Deschner
Division of Pediatric Rheumatology and Autoinflammation Reference Center Tuebingen (arcT), Department of Pediatrics, University Children’s Hospital Tuebingen, Hoppe-Seyler-Strasse 1, 72076 Tuebingen, Germany
1 shared publication - Paola Primatesta
Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland
1 shared publication - Philip N. Hawkins
National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 10 September 2013
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 139
Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
Background: The Cryopyrin-Associated Periodic Syndromes (CAPS) are a group of rare hereditary autoinflammatory diseases and encompass Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal Onset Multisystem Inflammatory Disease (NOMID). Canakinumab is a monoclonal antibody directed against IL-1 beta and approved for CAPS patients but requires post-approval monitoring due to low and short exposures during the licensing process. Creative approaches to observational methodology are needed, harnessing novel registry strategies to ensure Health Care Provider reporting and patient monitoring. Methods: A web-based registry was set up to collect information on long-term safety and effectiveness of canakinumab for CAPS. Results: Starting in November 2009, this registry enrolled 241 patients in 43 centers and 13 countries by December 31, 2012. One-third of the enrolled population was aged < 18; the overall population is evenly divided by gender. Enrolment is ongoing for children. Conclusions: Innovative therapies in orphan diseases require post-approval structures to enable in depth understanding of safety and natural history of disease. The rarity and distribution of such diseases and unpredictability of treatment require innovative methods for enrolment and follow-up. Broad international practice-based recruitment and web-based data collection are practical.
- 10 September 2013
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 139
Open AccessMethodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
Background: The Cryopyrin-Associated Periodic Syndromes (CAPS) are a group of rare hereditary autoinflammatory diseases and encompass Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal Onset Multisystem Inflammatory Disease (NOMID). Canakinumab is a monoclonal antibody directed against IL-1 beta and approved for CAPS patients but requires post-approval monitoring due to low and short exposures during the licensing process. Creative approaches to observational methodology are needed, harnessing novel registry strategies to ensure Health Care Provider reporting and patient monitoring. Methods: A web-based registry was set up to collect information on long-term safety and effectiveness of canakinumab for CAPS. Results: Starting in November 2009, this registry enrolled 241 patients in 43 centers and 13 countries by December 31, 2012. One-third of the enrolled population was aged < 18; the overall population is evenly divided by gender. Enrolment is ongoing for children. Conclusions: Innovative therapies in orphan diseases require post-approval structures to enable in depth understanding of safety and natural history of disease. The rarity and distribution of such diseases and unpredictability of treatment require innovative methods for enrolment and follow-up. Broad international practice-based recruitment and web-based data collection are practical.